Aripiprazole as a safer alternative for reproductive-age females with schizophrenia spectrum disorder: a case series

This case series investigates the use of aripiprazole as a safer alternative for reproductive-age females with schizophrenia experiencing galactorrhea due to antipsychotic treatment, primarily risperidone. Galactorrhea, the spontaneous discharge of breast milk, is a distressing side effect associated with elevated serum prolactin levels induced by certain antipsychotics. In three cases, females aged 30 to 40 diagnosed with schizophrenia and well-maintained on risperidone developed galactorrhea. Seeking to address both schizophrenia symptoms and galactorrhea, a gynecologist initiated cabergoline treatment to regulate prolactin levels. Simultaneously, the patients underwent a gradual transition from risperidone to aripiprazole. Over the course of the study, aripiprazole effectively mitigated galactorrhea, normalized serum prolactin levels, and maintained the stability of schizophrenia treatment. This case series suggests that aripiprazole may serve as a beneficial alternative for reproductive-age females, offering a balance between managing psychiatric symptoms and minimizing distressing side effects. Further research is warranted to validate these findings and explore the broader implications of aripiprazole in similar clinical contexts.